Accenture CEO Julie Sweet diagnoses breast cancer, plans surgery, while company ends DEI goals.

Accenture CEO Julie Sweet has been diagnosed with early-stage breast cancer and plans to undergo surgery next week. Despite the diagnosis, Sweet intends to continue her daily work responsibilities during her 12-16 week treatment period. The company's board supports her, and the Global Management Committee will ensure ongoing operations. Separately, Accenture has ended its diversity, equity, and inclusion (DEI) goals, stating that such policies will no longer impact employee performance assessments.

5 weeks ago
6 Articles

Further Reading